Pharmaceuticals discovered with AI
EFFICIENT DRUG DISCOVERY
twoXAR Pharmaceuticals has built a development portfolio targeting more than 18 different diseases. twoXAR’s unique approach to drug discovery combines steps from the traditional multi-step approach to R&D that severely limits the pace of drug discovery. This novel method – coupled with the company’s proprietary AI-driven platform – enables twoXAR to select a disease and initiate in vivo testing in months, instead of years.
The Applications of AI in Drug Discovery
twoXAR Corporate Seminar
July 19, 2019
LATEST EVENTS
New York, NY
February 10-11, 2020
twoXAR CEO, Andrew A. Radin, presents on the Applications of AI in Drug Discovery.
Tokyo, Japan
January 24, 2020
Join twoXAR CEO, Andrew A. Radin and Senior VP of Business Development, Allen Poirson, for an opportunity to meet with MIT-connected startups and hear about their impactful work and technology.
AAMA Global Healthcare Conference - AI: The Next Digital Frontier for Healthcare Innovation
San Francisco, CA
January 13, 2020
twoXAR CEO, Andrew A. Radin, participates in a panel discussion: Every Healthcare Professionals Dream: AI in Data, Diagnosis and Patient Care.
LATEST NEWS
Reframing the conversation: Drug discovery and AI at JPMorgan Chase Healthcare Conference
Andrew A. Radin, twoXAR CEO
January 17,2020
2019 Year in Review: Nine new projects, three announced partnerships
Andrew A. Radin, twoXAR CEO
December 13, 2019
© 2020 twoXAR, Incorporated | All Rights Reserved